Loading
companiesCompany
Bavarian Nordic
Bavarian Nordic is a Danish vaccine company whose poxvirus-based prostate cancer vaccine PROSTVAC failed the phase 3 PROSPECT trial in 2017, after which it concentrated on infectious disease vaccines such as its smallpox and mpox vaccine.
Also called: Bavarian Nordic A/S
Overview
Bavarian Nordic, based in Hellerup near Copenhagen and listed on Nasdaq Copenhagen, built its business on the modified vaccinia Ankara platform. In cancer it developed PROSTVAC (rilimogene galvacirepvec), a vaccinia and fowlpox vaccine against prostate-specific antigen, which did not improve survival in the phase 3 PROSPECT trial in metastatic castration-resistant prostate cancer reported in 2017, and CV301, a vaccine against CEA and MUC1 tested with checkpoint inhibitors. The company now focuses on travel and public health vaccines. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Headquarters
Hellerup, DK
Scorecard
All companies#391of 1244 companies, score 9
- modalities +2
- registry trials +10
- failures -3
0 approved, 0 in phase 3, 0 earlier, 0 targets, 23 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Withdrawnvaccine
A vaccine made from two viruses carrying the PSA gene, meant to teach the immune system to attack prostate cancer. The big trial found it did nothing at all.
Similar pages
- CompanyForesee Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Prostate cancer.
- CompanyOakwood Laboratories
Shares Pivotal (registrational) trial, Clinical trial, Prostate cancer.
- CompanyIonis Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Prostate cancer.
- TrialIMPACT (sipuleucel-T)
Shares PROSTVAC, PROSPECT, Prostate cancer.
- CompanyPregLem
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyImmunitor
cancers
fronts
technologies
drugs
Withdrawnvaccine